top of page


The latest on our CAR-T technology and more, presented at Myeloma Australia’s 4th National Myeloma Workshop

Novel antigens LMA and KMA are expressed on malignant bone marrow plasma cells from patients at all stages of multiple myeloma 

What makes our immunotherapies different on the large and growing multiple myeloma treatment market

HaemaLogiX company overview with CEO Bryce Carmine - October, 2022

Chief Manufacturing and Development Officer Tertia Dex explains the KappaMab manufacturing process

HaemaLogiX's Mary Sartor's presentation to the 63rd Annual ASH Annual Meeting in Atlanta, Georgia 2021

How KappaMab works. KappaMab is a monoclonal antibody developed by HaemaLogiX to treat blood cancers, with an initial focus on multiple myeloma.

bottom of page